Reported 2 days ago
Novo Nordisk and Regeneron Pharmaceuticals are struggling this year, with share prices down 18% and 19% respectively, failing to keep pace with a rising S&P 500. Despite facing challenges such as increased competition and clinical setbacks, both companies possess strong growth potential due to promising pipelines and innovative treatments. Investors may find value in these stocks for long-term gains, especially as both companies are taking steps to revitalize their product offerings and return capital to shareholders.
Source: YAHOO